Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Enovix Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.5 (market cap $5.07B), while Enovix Corporation trades at $4.82 (market cap $1.06B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 4.8× Enovix Corporation's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ACAD | ENVX | |
|---|---|---|
Market Cap | $5.07B | $1.06B |
Sector | Health | Technology |
52-Week High | $29.41 | $13.19 |
52-Week Low | $20.06 | $3.68 |
Enterprise Value | $4.19B | $1.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
ENVX is trading at $4.825, up 3.99% with strong analyst support (75% buy ratings) and a $12.38 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics, with recent earnings beats and strategic leadership appointments driving optimism. Revenue growth remains modest at $31.82M for 2025, but significant cash burn and negative margins highlight execution risks as the company scales battery production.
The outlook balances high growth potential in advanced battery technology against substantial financial losses. Investment opportunity lies in market leadership in silicon-anode batteries and recent operational improvements, while risks include persistent cash burn and competitive pressures in the evolving energy storage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
